Viewing StudyNCT06448962



Ignite Creation Date: 2024-06-16 @ 11:51 AM
Last Modification Date: 2024-10-26 @ 3:31 PM
Study NCT ID: NCT06448962
Status: COMPLETED
Last Update Posted: 2024-06-07
First Post: 2024-06-03

Brief Title: Phase 3 Study to Evaluate the Efficacy and Safety of Co-administrated AD-2021 and AD-2022
Sponsor:
Organization: Addpharma Inc

Study Design

Study Type: INTERVENTIONAL
Expanded Access Type Individual: None
Expanded Access Type Intermediate: None
Expanded Access Type Treatment: None
Patient Registry: None
Target Duration: None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention: None
Bio Spec Description: None
Enrollment Count: 109
Enrollment Type: ACTUAL
Design Primary Purpose:
Design Masking:
Phases:
Name
PHASE3
Observational Models:
Time Perspective List:
Who Masked List: